OBJECTIVES: We previously reported that stromal cell-derived factor-1α (SDF-1α, a homing signal for recruiting endothelial progenitor cells (EPC) to areas of neovascularization), is down-regulated in diabetic wounds (Gallagher et al, J Clin Invest. 2007;117:1249-1259). We now investigate signals whereby mature endothelial cells (EC) and circulating EPC achieve SDF-1α-mediated EPC homing. METHODS: SDF-1α in diabetic wounds were therapeutically increased by injection of SDF-1α-engineered bone marrow-derived fibroblasts versus control cells (N = 48 [20, non-obese diabetic (NOD)], [28, streptozotocin-C57]). Polymerase chain reaction-array gene expression differences were validated by Western blotting and immunohistochemistry. The role of adhesion molecule(s) in mediating SDF-1α-induced EPC homing, and wound healing was furthered studied using antagonists in vitro and in vivo. RESULTS: Increasing wound SDF-1α via cell-based therapy promotes healing in diabetic mice (∼20% increase in healing rates by day 3, P = 0.006). SDF-1α increased EC-EPC adhesion and specifically upregulated E-selectin expression in human microvascular EC (2.3-fold increase, P < 0.01). This effect was also significant in blood vessels of the experimental mice and resulted in increased wound neovascularization. The regulatory effects of SDF-1α on EC-EPC adhesion and EPC homing were specifically mediated by E-selectin, as the application of E-selectin antagonists significantly inhibited SDF-1α-induced EC-EPC adhesion, EPC homing, wound neovascularization, and wound healing. CONCLUSIONS: SDF-1α-engineered cell-based therapy promotes diabetic wound healing in mice by specifically upregulating E-selectin expression in mature EC leading to increase EC-EPC adhesion, EPC homing, and increased wound neovascularization. These findings provide novel insight into the signals underlying the biological effect of SDF-1α on EPC homing and point to E-selectin as a new potential target for therapeutic manipulation of EPC trafficking in diabetic wound healing.
OBJECTIVES: We previously reported that stromal cell-derived factor-1α (SDF-1α, a homing signal for recruiting endothelial progenitor cells (EPC) to areas of neovascularization), is down-regulated in diabetic wounds (Gallagher et al, J Clin Invest. 2007;117:1249-1259). We now investigate signals whereby mature endothelial cells (EC) and circulating EPC achieve SDF-1α-mediated EPC homing. METHODS:SDF-1α in diabetic wounds were therapeutically increased by injection of SDF-1α-engineered bone marrow-derived fibroblasts versus control cells (N = 48 [20, non-obese diabetic (NOD)], [28, streptozotocin-C57]). Polymerase chain reaction-array gene expression differences were validated by Western blotting and immunohistochemistry. The role of adhesion molecule(s) in mediating SDF-1α-induced EPC homing, and wound healing was furthered studied using antagonists in vitro and in vivo. RESULTS: Increasing wound SDF-1α via cell-based therapy promotes healing in diabeticmice (∼20% increase in healing rates by day 3, P = 0.006). SDF-1α increased EC-EPC adhesion and specifically upregulated E-selectin expression in human microvascular EC (2.3-fold increase, P < 0.01). This effect was also significant in blood vessels of the experimental mice and resulted in increased wound neovascularization. The regulatory effects of SDF-1α on EC-EPC adhesion and EPC homing were specifically mediated by E-selectin, as the application of E-selectin antagonists significantly inhibited SDF-1α-induced EC-EPC adhesion, EPC homing, wound neovascularization, and wound healing. CONCLUSIONS:SDF-1α-engineered cell-based therapy promotes diabetic wound healing in mice by specifically upregulating E-selectin expression in mature EC leading to increase EC-EPC adhesion, EPC homing, and increased wound neovascularization. These findings provide novel insight into the signals underlying the biological effect of SDF-1α on EPC homing and point to E-selectin as a new potential target for therapeutic manipulation of EPC trafficking in diabetic wound healing.
Authors: Susan M Majka; Kathyjo A Jackson; Kirsten A Kienstra; Mark W Majesky; Margaret A Goodell; Karen K Hirschi Journal: J Clin Invest Date: 2003-01 Impact factor: 14.808
Authors: Maria B Grant; W Stratford May; Sergio Caballero; Gary A J Brown; Steven M Guthrie; Robert N Mames; Barry J Byrne; Timothy Vaught; Polyxenie E Spoerri; Ammon B Peck; Edward W Scott Journal: Nat Med Date: 2002-06 Impact factor: 53.440
Authors: Katherine A Gallagher; Zhao-Jun Liu; Min Xiao; Haiying Chen; Lee J Goldstein; Donald G Buerk; April Nedeau; Stephen R Thom; Omaida C Velazquez Journal: J Clin Invest Date: 2007-05 Impact factor: 14.808
Authors: Nathan J Thyparambil; Lisa C Gutgesell; Bradley A Bromet; Lauren E Flowers; Samantha Greaney; Delbert E Day; Julie A Semon Journal: J Mater Sci Mater Med Date: 2020-03-23 Impact factor: 3.896
Authors: Antoine J Ribieras; Yulexi Y Ortiz; Yan Li; Carlos T Huerta; Nga Le; Hongwei Shao; Roberto I Vazquez-Padron; Zhao-Jun Liu; Omaida C Velazquez Journal: Front Cardiovasc Med Date: 2022-06-16
Authors: Zhao-Jun Liu; Yurong Tan; Gary W Beecham; David M Seo; Runxia Tian; Yan Li; Roberto I Vazquez-Padron; Margaret Pericak-Vance; Jeffery M Vance; Pascal J Goldschmidt-Clermont; Alan S Livingstone; Omaida C Velazquez Journal: Atherosclerosis Date: 2012-05-18 Impact factor: 5.162
Authors: Diego M Castilla; Zhao-Jun Liu; Runxia Tian; Yan Li; Alan S Livingstone; Omaida C Velazquez Journal: Ann Surg Date: 2012-10 Impact factor: 12.969
Authors: Zhao-Jun Liu; Pirouz Daftarian; Letícia Kovalski; Bo Wang; Runxia Tian; Diego M Castilla; Emre Dikici; Victor L Perez; Sapna Deo; Sylvia Daunert; Omaida C Velazquez Journal: PLoS One Date: 2016-04-22 Impact factor: 3.240